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Abstract Using the murine teratocarcinoma cell line F9 we
investigated the influence of serum stimulation and cisplatin
treatment on the p53, CK2, MDM2 levels. Both treatments led
to an increase of p53, though with different kinetics; the other
proteins investigated were not affected. We present direct
evidence by immunoprecipitation for an association of protein
kinase CK2 holoenzyme (K2L2), p53, and the ribosomal protein
L5. The results suggest complexes between the CK2 holoenzyme
and p53 but also p53/CKL complexes. Furthermore we provide
evidence for the existence of high molecular mass complexes of
CK2 in vivo. This is the first evidence that, under physiological
conditions, protein kinase CK2 does not exist solely as a
heterotetramer, but predominantly in association with other
proteins.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Protein-protein interaction studies are becoming more and
more the focus of general interest. Especially since the intro-
duction of the yeast two-hybrid system almost a decade ago
[1] the number of potential interacting proteins has increased
considerably. Protein kinase CK2 is no exception. Recently a
number of interacting proteins were identi¢ed [2,3], among
them A-Raf [4,5], ribosomal protein L5 [2,6] and others.
The yeast two-hybrid results suggesting an interaction be-
tween CK2L and A-Raf were con¢rmed in the baculovirus
system showing a stimulatory e¡ect on A-Raf kinase inas-
much as MEK phosphorylation was severalfold increased
[4,5].
Here we present new evidence for an in vivo association of
CK2 subunits with ribosomal protein L5 in non-overexpress-
ing cells. Interestingly, L5 has been found complexed with
MDM2 and MDM2/p53 complexes [7]. Since CK2 can phos-
phorylate p53 [8] and associate with p53 [9^11], a possible
higher order complex formation including CK2/L5/p53 and
MDM2 is suggestive. Moreover, it was shown that MDM2
is a substrate for CK2 and that p53 can enhance this phos-
phorylation [12].
Our present aim was to follow a strategy where a mamma-
lian cell line ^ overproducing neither protein kinase CK2 sub-
units K and L nor the interacting partners under investigation,
i.e. p53, protein L5 ^ was used throughout the experiments.
It was shown previously that the level of p53, after treat-
ment of cells with serum or a mitogen, increased markedly
(for review see [13]). However, a large body of evidence sug-
gests that stabilization of p53 protein is the main mechanism
to increase its levels. Thus stabilization occurs as a result of a
decrease in degradation that increases the half-life of p53. One
possibility to increase levels of p53 protein is by applying
DNA-damaging agents, e.g cisplatin [14^16].
By applying a semiquantitative immunodetection method to
follow the amounts of p53, L5, MDM2 and CK2 over a time
course of 4 h we discovered that p53, after treatment of the
cells with cisplatin, increased about 10-fold in less than 2 h
after the insult.
2. Materials and methods
2.1. Cell culture
The mouse embryonal teratocarcinoma cell line F9 was obtained
from the American Type Culture Collection (ATCC). Cells were
grown on tissue culture plates treated with 0.1% gelatin at 37‡C in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
10% fetal calf serum. Subcon£uent cultures (cell density about 70^
80%) were used throughout the experiments. The cells were treated
with 0.01 mg/ml cis-diamminedichloroplatinum(II) (cisplatin) for 4 h
or as indicated in the ¢gure legends.
2.2. Preparation of crude cell extracts and chromatographic analysis
Cells were rinsed three times with phosphate bu¡ered saline (PBS)
and then resuspended in bu¡er containing 25 mM Tris-HCl pH 8.5,
1 mM DTT, 100 mM NaCl and a cocktail of inhibitors (Boehringer
Mannheim). Disruption of the cells was carried out by sonication
followed by removal of cellular debris with a 4000Ug centrifugation
step for 20 min at 4‡C.
The supernatant was immediately used for immunoprecipitation or
for chromatographic analysis. Samples assigned for gel ¢ltration were
previously equilibrated in bu¡ers containing 25 mM Tris-HCl pH 8.5,
150 mM NaCl or 1 M NaCl before loading onto a Smart System
Superose 6 (Pharmacia) column.
2.3. Antibodies
Monoclonal antibody PAb 200.47 was kindly provided by Dr. C.
Goetz (University of Saarland, Homburg/Saar, Germany). Puri¢ed
anti-monoclonal p53 antibody (Ab-1) and anti-CK2K and anti-
CK2L antibodies were obtained from Calbiochem while anti-polyclo-
nal biotinylated p53 antibody was purchased from Boehringer Mann-
heim. Anti-monoclonal MDM2 antibody (SMP14) was obtained from
Santa Cruz. For the immunoprecipitation polyclonal antibodies from
rabbits directed against the human recombinant CK2 subunits or
against a peptide of human L5 protein were used.
2.4. Immunoprecipitation
Cell extracts (400 Wg) were diluted in IP bu¡er (50 mM Tris-HCl
pH 8, 150 mM NaCl, 5 mM EDTA, 0.05% NP40, 0.02% NaN3, 0.2%
BSA, cocktail of inhibitors) and incubated with monoclonal or poly-
clonal antibodies overnight at 4‡C in a total volume of 200 Wl. The
complexes were precipitated by incubation with protein A-agarose
(Boehringer Mannheim) for 4 h at 4‡C. Immunoprecipitates were
washed ¢ve times with IP bu¡er and once with PBS and then sub-
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jected to protein kinase assays or analyzed on SDS-polyacrylamide
gel.
2.5. Protein kinase assay
After treatment with serum or cisplatin for the times indicated in
the ¢gure legends, di¡erent amounts (1, 2.5, 5 Wg) of F9 crude cell
extracts were assayed at 37‡C for 5 min using the synthetic peptide as
a substrate (RRRDDDSDDD) [17,18]. 1 U of CK2 activity is de¢ned
as the amount of activity necessary to transfer (1 nmol phosphate/
min)W1031 into the synthetic peptide substrate at 37‡C.
2.6. SDS-polyacrylamide gel electrophoresis and Western blot analysis
SDS-PAGE was carried out as previously described [12]. For the
immunodetection of our proteins equal amounts of proteins were
applied to the gel, based on results from protein determination of
the cell extracts. However, in order to ensure maximum comparabil-
ity, a so-called match gel was run ¢rst. The proteins were Coomassie
stained and according to visual evaluation, if necessary, matched. If
matching was successful, the gel for blotting followed. One blot was
always used for the detection of all proteins of interest. This guaran-
teed that all proteins had undergone the same treatment and that
transfer and washing conditions were always applied to all proteins
in the same way. This was achieved by cutting the blot horizontally
into several strips using the rainbow markers located on both sites to
identify the position of the individual proteins, e.g. MDM2 (ca.
90 kDa), p53 (ca. 53 kDa), CK2K (ca. 44 kDa), L5 (ca. 34 kDa)
and CK2L (ca. 26 kDa). Needless to say, before this protocol was
applied, each antibody was tested on the whole blot in order to make
sure that there were no unspeci¢c cross-reactions. Any possible tech-
nical alterations would a¡ect all proteins equally. The transfer from
the gel to the membrane was also monitored by staining the mem-
brane with Ponceau red and by staining the gel after the transfer with
Coomassie blue.
3. Results
3.1. Short-time serum stimulation of F9 cells
In order to study the e¡ect of short-time serum stimulation
(4 h) on the expression of the CK2 subunits K and L, p53 and
MDM2, F9 cells were starved for 48 h and stimulated with
fresh medium containing 10% FCS. Cells were harvested at
the times indicated and CK2 activity was determined. As one
can see from the CK2 activity distribution no signi¢cant
changes were observed (Fig. 1A). The individual proteins
were also detected by immunostaining using speci¢c antibod-
ies. Equal amounts of protein were loaded on a gel. The
immunoblots of the K and L subunits (Fig. 1A) did not
show signi¢cant di¡erences in signal intensity over the time
period investigated. Hence, the results obtained are in agree-
ment with the observed unchanged CK2 activity before and
after serum stimulation (Fig. 1A). The same is true for the
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Fig. 1. A: Immunoblots showing the detection of proteins MDM2, p53, CK2K and L subunits together with the protein kinase CK2 activity
(lower graph) over a time range from t=0 until 4 h after serum stimulation. Prior to serum stimulation the F9 cells were starved for 2 days by
growth on DMEM in the absence of fetal calf serum. B: Same as in A, except that the cells were grown on DMEM, 10% FCS for 2 days after
seeding before the addition of cisplatin.
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MDM2 protein. Here too, we did not see any alterations in
protein expression. A completely di¡erent picture arose from
the time course of p53 where we observed a weak but distinct
signal in the starved cells (t = 0). 30 min after serum stimula-
tion the amount of p53 dropped by more than 50%, to a very
faint band. But 90 min after serum stimulation the quantity of
p53 was about 3^4-fold above the amount found in starved
cells and it remained constant over the rest of the stimulation
period.
3.2. Treatment of F9 cells with cisplatin
Next, we wanted to answer the question whether treatment
of the cells with cisplatin (DNA-damaging agent leading to
stabilization of p53) would have a similar e¡ect. We observed
that as in the case of serum stimulation CK2 activity was
una¡ected. Also the amount of the CK2 subunits K and L
and of the oncogene product MDM2 was unchanged over
the 4 h drug treatment. Again, in the case of p53 we found
a background level of p53 before cisplatin was added. After
30 min of cisplatin treatment we observed a decline of the p53
level. However, 60 min later the p53 expression level was back
to that found before treatment with the drug. After 90 min the
amount of p53 had already risen above the level found in
starved cells. A doubling of p53 in comparison to the back-
ground level was observed 90 min after drug treatment. How-
ever, 4 h after drug treatment there was still an increase no-
ticeable in contrast to the p53 alterations observed after serum
stimulation where the maximum was reached after 90 min
(Fig. 1B).
3.3. Immunoprecipitation with anti-CK2K
In order to answer the question whether we can demon-
strate mutual association of protein L5, CK2, and p53, im-
munoprecipitation experiments were conducted in mammalian
cells that do not overexpress these proteins under investiga-
tion. First we used a polyclonal antibody directed against
CK2K (IPK). The precipitated complexes were analyzed on
SDS-PAGE followed by Western blotting and immunostain-
ing using monoclonal antibodies directed against CK2K
(WBK), CK2L (WBL) and p53 (WBp53). We can see that
both CK2 subunits are detected, supporting the notion that
the holoenzyme was precipitated with the anti-CK2K antibody
(Fig. 2A). The three membrane strips were incubated for im-
munodetection for equal times. This should not only allow the
qualitative detection but also give a semi-quantitative estimate
of the relative distribution of the three proteins in the extracts.
Despite the di¡erence in avidity of the antibodies used for the
detection of the CK2 subunits (1AD9 and 6D5) we could
establish ^ using CK2 holoenzyme as an internal standard
for a 1:1 subunit detection ^ a suitable dilution ratio permit-
ting the detection of imbalances in the CK2 subunit ratio in
cell extracts. There is no di¡erence in the amount of p53 from
serum-stimulated cells (S) and those that had undergone cis-
platin treatment (Pt). C is the control where pre-immune se-
rum was used for the immunoprecipitation.
3.4. Immunoprecipitation with anti-CK2L
Fig. 2B shows the results obtained when anti-CK2L was
used for the IP. The ¢rst lane is again the control, where a
pre-immune serum was used for the immunoprecipitation.
The second lane shows the results when serum-stimulated
cell extracts were used and the third lane shows cisplatin-
treated cell extracts after immunoprecipitation.
Clearly, in the case of CK2K and L the result obtained is as
expected. The antibody directed against the L subunit precip-
itates the holoenzyme and thus both subunits should be de-
tectable (Fig. 2B). However, in contrast to Fig. 2A (immuno-
precipitation with anti-CK2K antibody), Fig. 2B shows that
the CK2 subunits were not detected equally well, despite the
same antibody dilutions as used in Fig. 2A. We detected less
CK2K than CK2L (Fig. 2B). This result is the same for serum-
stimulated cells (S) and cisplatin-treated cells (Pt) (Fig. 2B).
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Fig. 2. A: Immunoblots from immunoprecipitation experiments
(IPs) using a polyclonal rabbit antibody directed against the human
CK2K subunit. The preimmune serum of the rabbit from which the
antibody was obtained served as a control (C). 400 Wg of a F9 cell
extract was used for each IP. The extracts derived from cells which
had been serum-stimulated (S) or which had been subject to cispla-
tin treatment (Pt). After IP the material was analyzed by SDS-
PAGE and subsequently transferred to a membrane by Western
blotting. The proteins of interest were visualized using an anti-p53
antibody (polyclonal biotinylated) and by using the monoclonal
antibodies directed against CK2K (1AD9) and CK2L (6D5). B: Im-
munoblots from IPs using a polyclonal rabbit antibody directed
against the human CK2L subunit. Otherwise everthing was the same
as in A. C: Immunoblots from IPs using a polyclonal rabbit anti-
body directed against the human ribosomal protein L5. Otherwise
everthing was the same as in A.
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The second interesting observation is that the amount of
p53 precipitated by the anti-CK2L antibody is much higher
than the amount pulled down by the anti-CK2K antibody
(Fig. 2A) albeit the di¡erence in the serum-stimulated cells
is not that drastic with cisplatin treatment. About 3^5 times
more p53 is precipitated from cisplatin-treated cell extracts
than is the case from serum-stimulated extracts (Fig. 2B).
The results, both with serum and with cisplatin treatment,
support the notion of the existence of two CK2L populations,
namely together with CK2K in a complex with p53 and CK2L
by itself complexed to p53 (no CK2K present).
3.5. Immunoprecipitation with anti-L5 antiserum
Since p53, MDM2 and L5 were found to be immunopreci-
pitated in a complex we wanted to answer the question
whether we could also ¢nd a complex involving L5, p53 and
CK2. The experimental setup was as already described in the
previous experiment. A polyclonal antibody directed against
human protein L5 was applied. No signi¢cant di¡erence was
found when we looked for the presence of the CK2 subunits K
and L (Fig. 2C) either in serum-stimulated or in cisplatin-
treated cells. Immunodetection of p53 showed that p53 was
present implying that the L5 antibody had precipitated L5,
p53 and CK2 holoenzyme. There was signi¢cantly more p53
in the case of cisplatin-treated cells. So far we have no evi-
dence for an in vivo association of MDM2 and CK2 using an
anti-MDM2 antibody. Yet there is evidence for such a com-
plex formation in the yeast two-hybrid system (Boldyre¡ et
al., personal communication).
3.6. Characterization of high molecular mass complexes
involving MDM2, p53, CK2
A cellular extract as was used for the immunoprecipitation
experiments was analyzed on Superose 6 using the Pharmacia
SMART system chromatographic equipment. The proteins of
interest were detected by immunoblotting using speci¢c anti-
bodies. The ¢rst eight fractions did not contain any protein.
Hence, Western blotting analysis was done from fractions 8^
18. From the marker distribution the interesting fractionation
range was between fraction 13 (thyroglobulin, 670 kDa) and
fraction 19 (myoglobin, 17 kDa). Fig. 3A shows clearly that at
150 mM NaCl the p53 protein is distributed over a molecular
mass range from 125 kDa to over 1000 kDa. CK2 was present
mainly in fractions 14 and 15 which correspond to a molec-
ular mass range of 300^500 kDa. But we also found a small
amount of p53 protein in fraction 16 roughly at the position
of the IgG, where the CK2 holoenzyme in an K2L2 con¢gu-
ration would be expected. MDM2 is con¢ned to fractions 16
and 17 corresponding to a molecular mass range of 125^200
kDa. The results described above were con¢rmed by immu-
noprecipitation studies using a polyclonal anti-CK2K and de-
tecting L5 and p53 and by using an anti-CK2L antibody also
detecting p53 and L5. The observed protein distribution pro-
¢le shown in the immunoblots (Fig. 3A,B) corresponds to
what we also saw after immunoprecipitation of the individual
fractions supporting the notion that we are dealing with asso-
ciation and not merely with co-sedimentation (results not
shown).
Fig. 3B shows the analysis in the presence of 1 M NaCl.
Western blot was done from fractions 9^19. The MDM2 pro-
tein is shifted almost exclusively to fraction 17 which corre-
sponds to Mr 150 000. But also in the case of the CK2 sub-
units we observed a distinct shift to the lower molecular mass
species. CK2 is predominantly found in fractions 16 and 17,
which is exactly the position where it would band as a hetero-
tetramer. The same holds true for the L subunit. Only p53
was almost unchanged, i.e. sedimenting in a range from frac-
tions 10 to 17 (vs. 9^17 at 150 mM NaCl). It is certainly true
that a large amount of p53 was found to sediment in fraction
10 (E1000 kDa) at physiological salt concentration, whereas
at 1 M salt the maximum seems to be at fractions 14 and 15
(400^600 kDa).
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Fig. 3. A: Immunoblots from crude F9 extracts which had been cis-
platin-treated for 4 h and then analyzed on Superose 6 gel ¢ltration.
The fractions were analyzed on SDS-PAGE and then transferred to
membranes by Western blotting. The individual proteins were vis-
ualized by speci¢c antibodies, e.g. anti-MDM2, anti-p53, anti-CK2K
and L. The gel ¢ltration was carried out in the presence of 0.15 M
NaCl. B: Same as A, except that the gel ¢ltration was carried out
in the presence of 1 M NaCl.
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4. Discussion
We wanted to study the in£uence of serum and cisplatin
treatment on the expression and association of CK2 subunits
K and L with proteins L5, MDM2 and p53. We applied im-
munodetection methods in order to follow the fate of p53
after serum stimulation and cisplatin treatment. In contrast
to radioactive labeling of the cells, where predominantly pro-
tein new synthesis is measured, the immunological detection
makes it possible to follow (i) the actual distribution and (ii)
protein new synthesis. A prerequisite for the direct immuno-
detection of p53 in crude extracts by analysis on Western
blots without prior labeling the cells, however, is the avail-
ability of a sensitive detection method. We have applied 1,2-
dioxetan chemoluminescence substrates (Tropix, PE Applied
Biosystems, 1997) which deliver a higher light intensity and
hence a higher sensitivity in the detection of alkaline phospha-
tase (AP)-labeled immunocomplexes on blotting membranes
[19]. Furthermore, an excess of substrate leads to light emis-
sion over 24 h and is directly proportional to the AP enzyme
concentration. Hence, semi-quantitative determinations are
possible.
The level of p53 in cells prior to serum stimulation and
cisplatin treatment (t = 0 cells) was compared with the amount
of p53 found after treatment. For a positive control we used
extracts from SV80 cells where p53 is always found in a stable
form owing to the presence of the large T antigen in these cells
[20,21].
Before serum stimulation, cells were grown in the absence
of serum for 2 days. Cisplatin treatment was initiated 2 days
after seeding the cells and culturing in DMEM+10% FCS.
There was no di¡erence in the intensity of the MDM2 and
CK2 subunit detection throughout the time course (Fig.
1A,B). However, p53 was a¡ected. The activity of CK2 seems
to be on average somewhat smaller in the cisplatin-treated
cells than in the serum-stimulated cells. A paired t-test re-
vealed a two-tailed P value of 0.0714, suggesting only margin-
al signi¢cance. Therefore, we believe that this activity di¡er-
ence is more apparent than real (Fig. 1A,B).
Thirty minutes after stimulation with serum one can see a
drastic drop in the p53 level which is followed by an increase
again. In serum-stimulated cells (Fig. 1A) the maximum level
of p53 reached within 90 min is about four times higher than
that seen in cells before serum treatment and it remains the
same up to 240 min. In the case of cisplatin-treated cells (Fig.
1B) the p53 level increased steadily up to and beyond 240 min.
After 240 min the amount of p53 was about eight times the
value found for untreated cells. From the kinetics one can
conclude that there are di¡erent mechanisms involved in the
two processes, i.e. after serum stimulation and cisplatin treat-
ment.
At ¢rst glance the results obtained here seem to di¡er from
the data obtained from 35S-labeled methionine cells and West-
ern blot detection of p53 where a maximum level of p53 ex-
pression was found 18 h after serum stimulation [22]. We
found a marked increase in the p53 level as early as 90 min
after serum treatment with no further increase over the fol-
lowing 4 h. After this relatively short time Reich and Levine
[22] had not detected any newly synthesized p53; only after 6
h a modest 10% of the maximum level was found. In the case
of cisplatin treatment new protein synthesis via transcription
can also be excluded because of the known e¡ect of cisplatin
as a DNA-damaging agent preventing any transcription.
Therefore, it is very likely that the newly synthesized p53
protein comes from an internal mRNA pool. This notion is
supported by data which showed in F9 cells that regulation of
p53 expression occurs at the level of mRNA abundance and
p53 protein stability [20]. In most of the cells investigated, also
in 3T3 cells, the interaction of MDM2 with p53 leads to the
proteolytic degradation of p53 with a relatively short half-life
of p53, i.e. 0.4 h [20,23]. In F9 cells the half-life of p53 was
determined to be 3 h [20^23] suggesting already an impair-
ment of the usual proteolytic degradation process of p53. It is
known that DNA damage leads to the activation of a DNA-
dependent protein kinase which phosphorylates MDM2 and
thus abolishes its p53 binding function [24], hence p53 is no
longer funneled into the proteolytic degradation pathway and
therefore increases steadily until the mRNA pool is exhausted.
In the case of the observed p53 increase following serum
stimulation we observed a maximum level of p53 after 90 min.
From then on no further p53 increase was observed. Obvi-
ously, another mechanism leads to the observed rapid increase
in p53 protein. Since the MDM2 protein is not phosphory-
lated by DNA-dependent protein kinase owing to the lack of
DNA damage we have to postulate that the newly synthesized
p53 observed is not the result of protein new synthesis via
transcription but rather the result of stored mRNA activation.
It is known that the induction of certain proteins by serum is
regulated at the level of translation [25^28].
In any case it is quite imaginable that the binding of p53 to
other proteins, e.g. the large T antigen as in SVT2 cells, leads
to an extended half-life of more than 22 h [20]. CK2 could
provide a similar protective function of MDM2 phosphoryla-
tion by DNA-activated protein kinases after DNA damaging.
In order to answer the question whether CK2 subunits can
be found associated with p53 in serum-stimulated and cispla-
tin-treated cells we carried out immunoprecipitation experi-
ments.
4.1. IPK and L from cisplatin-treated cells
Let us now ¢rst consider the cisplatin-treated cells. As one
can see in Fig. 2A the anti-K antibody precipitates both CK2
subunits in agreement with all evidence available so far that
the majority of CK2 is present as the holoenzyme but also p53
is detected, unambiguous proof of an association of CK2
holoenzyme and p53.
In Fig. 2B we see the result of immunoprecipitation using
an anti-CK2L antibody. In principle we expected the same
result as seen in Fig. 2A. Yet, when we look at the result of
the cisplatin-treated cells we see a change in the CK2 subunit
ratio. Undoubtedly, more CK2L is now detected but also sig-
ni¢cantly more p53.
One might argue that the CK2 subunit signals were alto-
gether weaker than in the case of IPK (Fig. 2A) suggesting
that the antibody directed against the L subunit is poor com-
pared to the K antibody. However, this is only more apparent
than real because we deliberately reduced the exposure time
because of the much stronger p53 signal observed in IPL as
compared to IPK seen in Fig. 2A. Therefore we believe that
the anti-L antibody not only precipitates the CK2 holoen-
zyme/p53 complex but also a p53/L complex which would
explain the observed di¡erences in signal intensities.
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4.2. IPK and L from serum-stimulated cells
In the case of the serum-stimulated cells we do not see a
di¡erence to the cisplatin-treated cells (Pt) in the case of IPK
(Fig. 2A, lane S). Again when we look at IPL (Fig. 2B) we see
an imbalance in the subunit ratio as for the cisplatin-treated
cells. However, there is much less p53 associated than is the
case in the cisplatin-treated cells. This is also in agreement
with the observations in the Western blots shown in Fig.
1A,B where the amount of p53 in cisplatin-treated cells 4 h
after drug application is estimated to be four times higher. We
postulate that beside the holoenzyme complex formation there
should also be other complexes not involving the CK2 holo-
enzyme but also the CK2L and perhaps other so far unknown
proteins.
The IPL5 from cisplatin-treated cells and after serum stim-
ulation gave evidence for the association of CK2 holoenzyme
(140 kDa), p53 (200 kDa) [29] and ribosomal protein L5 (34
kDa), a complex which would at least account for a total
molecular mass of roughly 370 000 Da. However, as was the
case with IPL (Pt) the amount of p53 associated with CK2 in
the cisplatin-treated cells was signi¢cantly higher suggesting
the formation of CK2/p53 complexes by cisplatin treatment.
In the light of the recent ¢nding that CK2L can interact with
Mos and A-Raf [30] the present ¢nding does not come as a
total surprise. What is, however, surprising is the association
with ribosomal protein L5 that has previously been shown to
be associated with MDM2/p53 complexes and MDM2 alone.
Based on the observations by Guerra et al. [12] that CK2
phosphorylates MDM2 much better in the presence of p53
than in its absence we may speculate about the existence of
higher molecular mass complexes in the cell involving CK2
(150 kDa), L5 (35 kDa), MDM2 (50^90 kDa), p53 (200 kDa).
The complexes could reach sizes of 430^475 kDa. Indeed
when we analyzed the extracts used for the IPs for microanal-
ysis on a SMART system involving a Superose 6 gel ¢ltration
column the presence of p53 was detected in a molecular mass
range from 150 000 to far over 1 million (the fractionation
range for Superose 6 is from 5U103 to 5U106 Da). At phys-
iological salt concentration CK2 was found in fractions over a
molecular mass range from 200 kDa to over 1 million.
MDM2 was found at 125^200 kDa allowing for a variety of
di¡erent complex formations. However, one would not neces-
sarily expect the S-value to be additive to the individual pro-
teins making up the complex so that high molecular mass
complexes would exhibit such S-values. Remarkable is the
stability of the p53 complexes which are only marginally al-
tered even at 1 M salt. As expected the complexes are mostly
unstable in high salt. This is also clearly shown in Fig. 3B
where only the p53 is still found at a molecular mass far
above 1 million. CK2 and MDM2 have shifted to the lower
sedimentation range.
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